Emergent BioSolutions (EBS) Net Income towards Common Stockholders Growth (5y) (2016 - 2026)
Emergent BioSolutions (EBS) Net Income towards Common Stockholders Growth (5y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Emergent BioSolutions | 383.54 Mn | 222.04 Mn | 84.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -37.22% |
| Dec 31, 2025 | -18.06% |
| Sep 30, 2025 | 5.33% |
| Jun 30, 2025 | -16.32% |
| Mar 31, 2025 | 49.39% |
| Dec 31, 2024 | -21.68% |
| Sep 30, 2024 | 21.59% |
| Jun 30, 2024 | -97.17% |
| Mar 31, 2024 | 18.60% |
| Dec 31, 2023 | -69.87% |
| Sep 30, 2023 | -70.96% |
| Jun 30, 2023 | -48.48% |
| Mar 31, 2023 | -106.99% |
| Dec 31, 2021 | 103.46% |
| Sep 30, 2021 | -105.16% |
| Jun 30, 2021 | 20.27% |
| Mar 31, 2021 | 61.02% |
| Dec 31, 2020 | 86.15% |
| Sep 30, 2020 | 57.45% |
| Jun 30, 2020 | 66.90% |